AR051919A1 - Compuesto derivado de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimientos para preparar el compuesto - Google Patents

Compuesto derivado de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimientos para preparar el compuesto

Info

Publication number
AR051919A1
AR051919A1 ARP050102470A ARP050102470A AR051919A1 AR 051919 A1 AR051919 A1 AR 051919A1 AR P050102470 A ARP050102470 A AR P050102470A AR P050102470 A ARP050102470 A AR P050102470A AR 051919 A1 AR051919 A1 AR 051919A1
Authority
AR
Argentina
Prior art keywords
compound
formula
cyclopentyl
reacting
onyl
Prior art date
Application number
ARP050102470A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0413770A external-priority patent/GB0413770D0/en
Priority claimed from GB0413764A external-priority patent/GB0413764D0/en
Priority claimed from GB0413757A external-priority patent/GB0413757D0/en
Priority claimed from GB0413758A external-priority patent/GB0413758D0/en
Priority claimed from GB0413768A external-priority patent/GB0413768D0/en
Priority claimed from GB0413763A external-priority patent/GB0413763D0/en
Priority claimed from GB0413765A external-priority patent/GB0413765D0/en
Priority claimed from GB0413769A external-priority patent/GB0413769D0/en
Priority claimed from GB0413766A external-priority patent/GB0413766D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR051919A1 publication Critical patent/AR051919A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Compuesto de derivado de benzazepina, de formula (1), donde R1 representa ciclopentilo o ciclobutilo; R2 representa piridin-3-ilo, piridin-2-ilo, 3-fluorofenilo, fenilo o piridazin-3-ilo, pirazin-2-ilo y R3 representa pirrolidin-2-onilo, 3-metil- imidazolidin-2-onilo, 1,3- oxazolidin-2-onilo o 3-metil-1,2,4-oxadiazol-5-ilo. Su uso para la fabricacion de un medicamento para tratar enfermedades neurologicas y composicion farmacéutica que lo comprende. Este compuesto se aplica en el tratamiento de trastornos neurologicos y psiquiátricos, tal como enfermedad de Alzheimer, demencia, déficit cognitivo, epilepsia, neuralgias, neuritis, dolor inflamatorio, incluida la osteoartritis, enfermedad de Parkinson, esclerosis multiple, accidente cerebrovascular, trastornos del sueno, incluida la narcolepsia; trastornos psiquiátricos, incluida la esquizofrenia, trastorno de hiperactividad con déficit de atencion, y depresion. Reivindicacion 9: Un procedimiento para la preparacion del compuesto 1-{6-[(3-ciclopentil-2,3,4,5-tetrahidro-1H-3-benzazepin-7-il)oxi]-3- piridinil}-2-pirrolidinona de acuerdo con la reivindicacion 2, caracterizado porque comprende: a) hacer reaccionar un compuesto de formula (2), con un compuesto de formula 3-(pirrolidin-2-ona)-piridin-6-il-L1, donde L1 representa un grupo saliente adecuado tal como un átomo de halogeno, por ejemplo bromo o yodo, o un grupo hidroxilo opcionalmente activado; o b) hacer reaccionar un compuesto de formula (3), con un compuesto de formula ciclopentil-L2, donde L2 representa un grupo saliente adecuado tal como un átomo de halogeno, por ejemplo bromo, yodo o tosilato; o c) hacer reaccionar un compuesto de formula (3) como se ha definido anteriormente, con ciclopentanona; o d) hacer reaccionar un compuesto de formula (4), donde L3 representa un grupo saliente adecuado tal como un átomo de halogeno, por ejemplo yodo, con pirrolidinona; o f) desproteger un compuesto protegido para producir 1-{6-[(3- ciclopentil-2,3,4,5-tetrahidro-1H-3-benzazepin-7-il)oxi]-3-piridinil}-2-pirrolidinona.
ARP050102470A 2004-06-18 2005-06-16 Compuesto derivado de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimientos para preparar el compuesto AR051919A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0413770A GB0413770D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413764A GB0413764D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413757A GB0413757D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413758A GB0413758D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413768A GB0413768D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413763A GB0413763D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413765A GB0413765D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413769A GB0413769D0 (en) 2004-06-18 2004-06-18 Novel compound
GB0413766A GB0413766D0 (en) 2004-06-18 2004-06-18 Novel compound

Publications (1)

Publication Number Publication Date
AR051919A1 true AR051919A1 (es) 2007-02-21

Family

ID=34971297

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102470A AR051919A1 (es) 2004-06-18 2005-06-16 Compuesto derivado de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimientos para preparar el compuesto

Country Status (7)

Country Link
US (1) US20070232590A1 (es)
EP (1) EP1756094A1 (es)
JP (1) JP2008502644A (es)
AR (1) AR051919A1 (es)
PE (1) PE20060302A1 (es)
TW (1) TW200611701A (es)
WO (1) WO2005123723A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60329123D1 (de) * 2002-12-20 2009-10-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
WO2007149728A2 (en) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
UA98772C2 (ru) 2006-06-23 2012-06-25 Эбботт Леборетриз Производные циклопропиламина как модуляторы н3-гистаминового рецептора
CL2008000596A1 (es) * 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
KR101516833B1 (ko) 2007-03-23 2015-05-07 위스콘신 얼럼나이 리서어치 화운데이션 체세포 재프로그래밍
MX2011000460A (es) * 2008-07-18 2011-03-15 Takeda Pharmaceutical Derivados de benzazepina y su uso como antagonistas de histamina h3.
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011083316A1 (en) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Benzazepine derivatives for the treatment of central nervous system disorders
UY33172A (es) 2010-01-08 2011-07-29 Takeda Pharmaceutical Derivados de benzazepina y su uso como antagonistas de histamina h3
WO2011083315A1 (en) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Compounds and their use
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210749A (en) * 1974-11-12 1980-07-01 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
ATE365209T1 (de) * 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US7229986B2 (en) * 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
GB0130576D0 (en) * 2001-12-20 2002-02-06 Cenes Ltd Dopamine D1 receptor agonist pro-drug compounds & derivatives
DE60304695T2 (de) * 2002-02-13 2006-09-21 Glaxo Group Ltd., Greenford 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo[d]azepin-derivate mit 5-hat-6-rezeptor affinität zur behandlung von erkrankungen des zentralnervensystems
US20050085461A1 (en) * 2002-02-13 2005-04-21 Cooper David G. Benzenesulfonamide derivatives
KR20040081201A (ko) * 2002-02-13 2004-09-20 글락소 그룹 리미티드 항정신병제로서 벤젠술폰아미드 유도체
GB0210762D0 (en) * 2002-05-10 2002-06-19 Glaxo Group Ltd Compounds
GB0224083D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
DE60329123D1 (de) * 2002-12-20 2009-10-15 Glaxo Group Ltd Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0405628D0 (en) * 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
WO2005123723A1 (en) 2005-12-29
PE20060302A1 (es) 2006-04-08
US20070232590A1 (en) 2007-10-04
TW200611701A (en) 2006-04-16
EP1756094A1 (en) 2007-02-28
JP2008502644A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
AR051919A1 (es) Compuesto derivado de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimientos para preparar el compuesto
US20120157458A1 (en) Imidazotriazinone compounds
TW200635589A (en) Therapeutic agents
US10131669B2 (en) Pyrazolopyrimidine compounds
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
CN112154145B (zh) 哌嗪氮杂螺衍生物
NZ600368A (en) Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators
US11319321B2 (en) [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
JP2018514552A (ja) Ｐｄｅ１阻害剤としてのイミダゾピラジノン
ATE453617T1 (de) Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien
NO20034031L (no) Substituerte pyrazol- og tiazolpyrimidiner
BR112015030678A8 (pt) derivados 4-amino-6-fenil-5,6-di-hidroimidazo [1,5-a] pirazina como inibidores de beta-secretase (bace), composição farmacêutica, processo para preparação da mesma, e usos na fabricação de medicamentos
US10738018B2 (en) Compounds for therapeutic use
JP2019534327A5 (es)
TW200635906A (en) Substituted triazolone, tetrazolone and imidazolone derivatives for use as a medicine
MX2018008653A (es) Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina .
DK2091942T3 (da) Substituerede pyrazinderivater til anvendelse som en medicin
US11077090B2 (en) Compounds and compositions and uses thereof
WO2023168298A2 (en) Compounds, compositions, and methods
BRPI0508124A (pt) 2-piridinil[7-(piridin-4-il)pirazolo[1,5-a]piridimidin-3-il] metanonas
RU2016132574A (ru) Органические соединения
IL194740A0 (en) Substituted pyrazinone derivatives for use as a medicine
US11053258B2 (en) Pyrimidine carboxamides as GSK-3 inhibitors
DE602005016244D1 (de) Benzoxazolonderivate, verfahren zu deren herstellung und deren anwendungen
RU2014110971A (ru) 1,4-диазабицикло[3.2.2]нонаны в качестве лигандов для нейронных никотиновых ацетилхолиновых рецепторов

Legal Events

Date Code Title Description
FB Suspension of granting procedure